3m Innovative Properties Company

The University of Texas System

Biothera Inc.

John P Vasilakos

Keith B Gorden

Mark A Tomai

Xiaohong Qiu

Willem Overwijk

Michael E Danielson

Nandita Bose

Cory L Ahonen

John T Capecchi

David M Hammerbeck

Joseph M Beaurline

Mary A Antonysamy

William J Grossman

Anissa S H Chan

Steven M Leonardo

Elaine A Egging

Michael J Reiter

Christopher D Gram

Jason R Fink

James M Elvecrog

Kevin S Gorski

Shalley K Gupta

Karen Elizabeth Johnson

Gary W Gullikson

James Elvecrog

Karen E Johnson

Injectable formulations comprising ethanol, sesame oil, and an Immune Response Modifier compound are disclosed. Methods of making the formulations and methods of using the formulations for treatment of a disease in a subject, e.g., neoplastic disease, comprising injecting the formulations into a subject hi need of treatment, are also provided.

Sesame oil based injection formulations

Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an Immune Response Modifier Compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds.

Methods and therapeutic combinations for treating tumors

Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.

Beta-glucan compounds, compositions, and methods

The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.

Therapeutic combinations and methods including IRM compounds

Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compounds so identified and pharmaceutical compositions including such compounds are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.

Selective modulation of TLR-mediated biological activity

Methods of eliciting a TLR8-mediated cellular response are disclosed. Such methods include administration of either a TLR8 agonist or a TLR8 antagonist to an IRM-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.

Methods and compositions related to IRM compounds and Toll-like receptor 8

A method of inducing the maturation of dendritic cells by stimulating immature dendritic cells with an imidazoquinoline type immune response modifying compound. Dendritic cells that have been matured in this manner display increased antigen presenting ability and may be used as immunotherapeutic agents.

Maturation of dendritic cells with immune response modifying compounds

Growing community of inventors

Saint Paul, MN, United States of America

John P Vasilakos